All In Biotech

Drug Trial Radar · NCT07753252

Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the Body

Phase 1, Open-label, Fixed-sequence Crossover Study to Investigate the Effect of Sevabertinib on the Pharmacokinetics of Metformin in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Aug 21, 2026

Primary completion

Oct 8, 2026

Study completion Oct 8, 2026

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Aug 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1 study in healthy adults looks at whether sevabertinib changes how the body handles metformin. The study is based on the idea that sevabertinib may block kidney transporters (proteins that move medicines) called MATE1 and MATE2-K, which help remove metformin from the body. Each participant receives a single dose of metformin alone, and later receives sevabertinib for several days and then takes metformin again while still taking sevabertinib. The study aims to learn how metformin, gets into, moves through, and out of the body when it is administered with sevabertinib. This is called "Pharmacokinetics". Furthermore, the study will help us learn about the safety and tolerability of sevabertinib and metformin when given alone or in combination.

Conditions

  • Healthy Participants

Interventions

  • MetforminDrug

    Immediate-release tablet, 500 mg; administered as a single 500 mg oral dose in Intervention Period 1 (Day 1) and as a single 500 mg oral dose in Intervention Period 2 (Day 1 of the combination phase, after sevabertinib pre-treatment)

  • Sevabertinib (BAY 2927088)Drug

    Film-coated tablet, 10 mg; administered as 20 mg BID (oral) pre-treatment in Intervention Period 2 and continued 20 mg BID during co-administration with metformin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC (Area Under the Curve) of metforminTime frame: Relative to metformin administration on Study Day 1 un until Study Day 4
  2. AUC(0-tlast) (Area Under the Curve from time 0 to tlast) of metforminTime frame: Relative to metformin administration on Study Day 1 un until Study Day 4
  3. Cmax (Maximum Plasma Concentration) of metforminTime frame: Relative to metformin administration on Study Day 1 un until Study Day 4

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Pharmacology of Miami - Oncology

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.